Equity Profile

BMRN

BioMarin Pharmaceutical Inc.

Health CareBiotechnology$11.4B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing innovative therapies for serious genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and fund future research.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BMRN Q2-2026 Earnings Preview

Context

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing innovative therapies for serious genetic diseases. With a market cap of $11 billion, it plays a crucial role in the health care sector, particularly in rare disease treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+117.28%

Avg Stock Reaction

-0.49%

Last Quarter Recap

In Q1-2026, BioMarin reported an EPS of $0.76, slightly below expectations. The stock reacted positively the next day, gaining 2.59%.

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to improving operational efficiencies.
Plans to enhance market access for existing products.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's history of beating EPS estimates. However, concerns about revenue growth persist.

Bull Case

If BioMarin can demonstrate strong revenue growth and positive pipeline updates, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet revenue expectations or provides disappointing updates on its drug pipeline, it could negatively impact the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth rate for the upcoming quarter?

Revenue growth is critical for investor confidence and reflects the company's ability to expand its market presence.

What updates can management provide on the status of their drug pipeline?

Pipeline progress is essential for understanding future revenue potential and the company's long-term viability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for BioMarin's pipeline to deliver unexpected positive results this quarter, given the recent advancements in clinical trials.

Supporting Evidence

The company's history of beating EPS estimates suggests potential for upside surprises.

Options pricing indicates a significant expected move, which may reflect investor sentiment about upcoming developments.

Management's previous commitments to operational efficiencies could lead to better-than-expected results.

Key Risk

If the company reports revenue growth below 5%, it could undermine the optimistic outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for revenue growth against the backdrop of pipeline developments and previous earnings performance.

Bull Confirmed If

Demonstrating revenue growth of at least 10% year-over-year would confirm the bull case.

Bear Confirmed If

A decline in revenue or negative updates on the drug pipeline would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±15.32%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±15.3% while BMRN has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

42.3%

Calls (10K)P/C Ratio: 0.20Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

History suggests that a strong earnings beat could lead to a positive reaction, with an average 1-day move of +2.36%.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further commentary.

Miss

A disappointing earnings report could lead to a decline, with history indicating an average 1-day move of -0.37% when misses occur.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue growth expectations for the upcoming quarter.
2Updates on the status of key drugs in the pipeline.
3Any commentary on market access strategies for existing products.
4Insights into operational efficiencies and cost management.
5Management's outlook on future growth and market conditions.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing innovative therapies for serious genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and fund future research.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BMRN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+117.28%

Avg Stock Reaction

-0.49%

Last Quarter Recap

In Q1-2026, BioMarin reported an EPS of $0.76, slightly below expectations. The stock reacted positively the next day, gaining 2.59%.

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to improving operational efficiencies.
Plans to enhance market access for existing products.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's history of beating EPS estimates. However, concerns about revenue growth persist.

Bull Case

If BioMarin can demonstrate strong revenue growth and positive pipeline updates, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet revenue expectations or provides disappointing updates on its drug pipeline, it could negatively impact the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth rate for the upcoming quarter?

Revenue growth is critical for investor confidence and reflects the company's ability to expand its market presence.

What updates can management provide on the status of their drug pipeline?

Pipeline progress is essential for understanding future revenue potential and the company's long-term viability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for BioMarin's pipeline to deliver unexpected positive results this quarter, given the recent advancements in clinical trials.

Supporting Evidence

The company's history of beating EPS estimates suggests potential for upside surprises.

Options pricing indicates a significant expected move, which may reflect investor sentiment about upcoming developments.

Management's previous commitments to operational efficiencies could lead to better-than-expected results.

Key Risk

If the company reports revenue growth below 5%, it could undermine the optimistic outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for revenue growth against the backdrop of pipeline developments and previous earnings performance.

Bull Confirmed If

Demonstrating revenue growth of at least 10% year-over-year would confirm the bull case.

Bear Confirmed If

A decline in revenue or negative updates on the drug pipeline would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±15.32%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±15.3% while BMRN has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

42.3%

Calls (10K)P/C Ratio: 0.20Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

History suggests that a strong earnings beat could lead to a positive reaction, with an average 1-day move of +2.36%.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further commentary.

Miss

A disappointing earnings report could lead to a decline, with history indicating an average 1-day move of -0.37% when misses occur.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue growth expectations for the upcoming quarter.
2Updates on the status of key drugs in the pipeline.
3Any commentary on market access strategies for existing products.
4Insights into operational efficiencies and cost management.
5Management's outlook on future growth and market conditions.